Cargando…

Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine

Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Nantel, Sabryna, Bourdin, Benoîte, Adams, Kelsey, Carbonneau, Julie, Rabezanahary, Henintsoa, Hamelin, Marie-Ève, McCormack, Deirdre, Savard, Patrice, Longtin, Yves, Cheng, Matthew P., De Serres, Gaston, Corbeil, Jacques, Gilca, Vladimir, Baz, Mariana, Boivin, Guy, Quach, Caroline, Decaluwe, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614167/
https://www.ncbi.nlm.nih.gov/pubmed/36311736
http://dx.doi.org/10.3389/fimmu.2022.930252
_version_ 1784820134635896832
author Nantel, Sabryna
Bourdin, Benoîte
Adams, Kelsey
Carbonneau, Julie
Rabezanahary, Henintsoa
Hamelin, Marie-Ève
McCormack, Deirdre
Savard, Patrice
Longtin, Yves
Cheng, Matthew P.
De Serres, Gaston
Corbeil, Jacques
Gilca, Vladimir
Baz, Mariana
Boivin, Guy
Quach, Caroline
Decaluwe, Hélène
author_facet Nantel, Sabryna
Bourdin, Benoîte
Adams, Kelsey
Carbonneau, Julie
Rabezanahary, Henintsoa
Hamelin, Marie-Ève
McCormack, Deirdre
Savard, Patrice
Longtin, Yves
Cheng, Matthew P.
De Serres, Gaston
Corbeil, Jacques
Gilca, Vladimir
Baz, Mariana
Boivin, Guy
Quach, Caroline
Decaluwe, Hélène
author_sort Nantel, Sabryna
collection PubMed
description Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects’ symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-9614167
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96141672022-10-29 Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine Nantel, Sabryna Bourdin, Benoîte Adams, Kelsey Carbonneau, Julie Rabezanahary, Henintsoa Hamelin, Marie-Ève McCormack, Deirdre Savard, Patrice Longtin, Yves Cheng, Matthew P. De Serres, Gaston Corbeil, Jacques Gilca, Vladimir Baz, Mariana Boivin, Guy Quach, Caroline Decaluwe, Hélène Front Immunol Immunology Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-γ secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects’ symptoms at diagnosis and/or serostatus prior to vaccination. None of the naïve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to naïve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection. Frontiers Media S.A. 2022-10-14 /pmc/articles/PMC9614167/ /pubmed/36311736 http://dx.doi.org/10.3389/fimmu.2022.930252 Text en Copyright © 2022 Nantel, Bourdin, Adams, Carbonneau, Rabezanahary, Hamelin, McCormack, Savard, Longtin, Cheng, De Serres, Corbeil, Gilca, Baz, Boivin, Quach and Decaluwe https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Nantel, Sabryna
Bourdin, Benoîte
Adams, Kelsey
Carbonneau, Julie
Rabezanahary, Henintsoa
Hamelin, Marie-Ève
McCormack, Deirdre
Savard, Patrice
Longtin, Yves
Cheng, Matthew P.
De Serres, Gaston
Corbeil, Jacques
Gilca, Vladimir
Baz, Mariana
Boivin, Guy
Quach, Caroline
Decaluwe, Hélène
Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title_full Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title_fullStr Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title_full_unstemmed Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title_short Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine
title_sort symptomatology during previous sars-cov-2 infection and serostatus before vaccination influence the immunogenicity of bnt162b2 covid-19 mrna vaccine
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614167/
https://www.ncbi.nlm.nih.gov/pubmed/36311736
http://dx.doi.org/10.3389/fimmu.2022.930252
work_keys_str_mv AT nantelsabryna symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT bourdinbenoite symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT adamskelsey symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT carbonneaujulie symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT rabezanaharyhenintsoa symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT hamelinmarieeve symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT mccormackdeirdre symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT savardpatrice symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT longtinyves symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT chengmatthewp symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT deserresgaston symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT corbeiljacques symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT gilcavladimir symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT bazmariana symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT boivinguy symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT quachcaroline symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine
AT decaluwehelene symptomatologyduringprevioussarscov2infectionandserostatusbeforevaccinationinfluencetheimmunogenicityofbnt162b2covid19mrnavaccine